Related Experiment Video
Updated: Jan 17, 2026
Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis
Huimin Chen1, Xiaotong Li2, Jihong Chen1
1Department of Gastroenterology, General Hospital of Northern Theater Command (Teaching Hospital of Dalian Medical University), Shenyang, China; Postgraduate College, Dalian Medical University, Dalian, China.
Background:
The primary goal of treatment for hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is to rapidly reduce blood triglyceride (TG) level to below 5.65 mmol/L. Evolocumab with a significant lipid-lowering effect, has been widely used for cardiovascular diseases. However, it has been rarely explored in HTG-AP.
Methods:
HTG-AP patients, who were admitted between January 2022 and February 2024, were retrospectively reviewed. They were further divided according to the use of evolocumab. Blood TG levels before treatment were compared with those after 1-2 days, 3-4 days, and 5-7 days of treatment.
Results:
Overall, 62 patients were included, of whom 30 (48.4 %) were in the evolocumab group and 32 (51.6 %) were in the non-evolocumab group. The median pre-treatment TG levels were not significantly different between them (22.17 mmol/L vs 16.94 mmol/L, P = 0.108). Blood TG levels after 1-2 days (P = 0.016) and 5-7 days (P = 0.007) were significantly higher in the evolocumab group than the non-evolocumab group. The proportion of TG < 5.65 mmol/L after 1-2 days (6/24 vs 11/23, P = 0.104) and 3-4 days (10/19 vs 14/20, P = 0.265) was not significantly different between them, but that after 5-7 days (9/15 vs 19/20, P = 0.033) was significantly lower in the evolocumab group than the non-evolocumab group.
Conclusion:
The addition of evolocumab to conventional lipid-lowering therapy did not produce any additional benefit in the reduction of blood TG levels in HTG-AP patients.
More Related Videos
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Related Concept Videos
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...